Postmenopausal Osteoporosis: A Clinical Review.

Area of Science:

• Gerontology
• Orthopedics
• Endocrinology

Background:

• Osteoporotic fractures are more prevalent than stroke, myocardial infarction, and breast cancer combined in postmenopausal women.
• Fractures lead to significant costs, disability, and mortality.
• Osteoporosis lacks overt symptoms, necessitating proactive risk assessment.

Purpose of the Study:

• To emphasize the importance of clinical fracture risk assessment for postmenopausal women.
• To outline recommendations for bone mineral density (BMD) testing and lifestyle interventions.
• To discuss pharmacological treatments and their management strategies for osteoporosis.

Main Methods:

• Clinical fracture risk assessment (FRAX) recommended at menopause.
• Bone mineral density (BMD) testing recommended at age 65 or earlier if risk factors are present.
• Evaluation of lifestyle factors including calcium, vitamin D, and weight-bearing exercise.

Main Results:

• Medical therapy is recommended for high-risk individuals identified by BMD or FRAX.
• Bisphosphonates allow for potential drug holidays; denosumab does not.
• Anabolic therapy is an option for higher-risk patients.

Conclusions:

• The benefits of hip fracture risk reduction significantly outweigh rare safety concerns like atypical femoral fracture and osteonecrosis of the jaw when treated per guidelines.
• Patient education and shared decision-making are vital for treatment adherence.